1,1-dicarboxamidocyclopropane | 5813-85-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,1-dicarboxamidocyclopropane
• 英文别名: 1,1-Dicarbamoyl-cyclopropan；Cyclopropan-1,1-dicarboxamid；cyclopropane-1,1-dicarboxylic acid amide [4-(3-fluoro-benzyloxy)-phenyl]-amide；cyclopropane-1,1-diamide；Cyclopropane-1,1-dicarboxylic acid amide ((3R*,5S*)-5-{cyclopropyl-[1-(3 methoxy-propyl)-1H-indol-3-ylmethyl]-carbamoyl}piperidin-3-yl)-amide；Cyclopropane-1,1-dicarboxylic acid amide {6-fluoro-3-[(E)-2-(4-fluorophenyl)-vinyl]-1H-indazol-5-yl}-amide；Cyclopropan-dicarbonsaeure-(1.1)-diamid；cyclopropane-1,1-dicarboxamide；Cyclopropan-1,1-dicarbamid；1,1-Cyclopropanedicarboxamide
• CAS: 5813-85-4
• 化学式: C₅H₈N₂O₂
• mdl: MFCD00721424
• 分子量: 128.131
• InChiKey: FEHLGOYZDFFMND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-dicarboxamidocyclopropane 在 copper(I) oxide 、 copper(II) acetate monohydrate 、 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 卡博替尼
  参考文献：
  名称：

  一种卡博替尼及其中间体的合成方法

  摘要：

  本发明提供一种卡博替尼及其中间体的合成方法，属于药物化学领域。本发明采用环丙烷‑1，1‑二甲酸胺为关键中间体，分别与取代氟苯和4‑((6，7‑二甲基‑喹啉‑4‑基)氧基)取代苯反应得到产品卡博替尼。本发明有效避免了副产物的产生，提高了制备卡博替尼的收率和原料的利用率，节约了生产成本，更适于工业化生产。

  公开号：

  CN112390749A
• 作为产物：
  描述：

  1,1-环丙基二羧酸二乙酯 在 氨 作用下， 生成 1,1-dicarboxamidocyclopropane
  参考文献：
  名称：

  Ingold; Sako; Thorpe, Journal of the Chemical Society, 1922, vol. 121, p. 1197

  摘要：

  DOI：

文献信息

• N-acylamino benzyl ether derivatives
  申请人：——

  公开号：US20030232883A1

  公开（公告）日：2003-12-18

  This invention relates to N-acylamino aryl derivatives of the formula 1 where R 1 , R 21 , R 22 , R 23 , R 3 , R 4 , R 5 R 6 , R 7 , R 8 , R, and n are as defined herein and where X is —CHRO, —OCHR—, —CH 2 S—, —SCH 2 —, —CH 2 CH 2 —, —CH═CH— or —C≡C—. The compounds of the invention are selective monoamine oxidase B inhibitors, and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B, for example, for the treatment of Alzheimer's disease or senile dementia.

  这项发明涉及公式1的N-酰氨基芳基衍生物，其中R1、R21、R22、R23、R3、R4、R5、R6、R7、R8、R和n如本文所定义，且X为—CHRO、—OCHR—、—CH2S—、—SCH2—、—CH2CH2—、—CH═CH—或—C≡C—。该发明的化合物是选择性的单胺氧化酶B抑制剂，因此它们在治疗由单胺氧化酶B介导的疾病中具有用途，例如用于治疗阿尔茨海默病或老年性痴呆症。
• c-MET MODULATORS AND METHOD OF USE
  申请人：BANNEN CANNE LYNNE

  公开号：US20070244116A1

  公开（公告）日：2007-10-18

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性，以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。更具体地，本发明提供了喹唑啉和喹啉，这些化合物抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导途径，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供制备上述化合物的方法和包含这些化合物的组合物。
• C-MET MODULATORS AND METHOD OF USE
  申请人：Bannen Canne Lynne

  公开号：US20070225307A1

  公开（公告）日：2007-09-27

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学入侵）的化合物。更具体地，该发明提供了喹唑啉和喹啉，它们能够抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导途径，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物和包含这些化合物的组合物的方法。
• CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
  申请人：Flynn Daniel L.

  公开号：US20100120806A1

  公开（公告）日：2010-05-13

  Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

  本发明的化合物在哺乳动物癌症治疗中具有实用性，特别是人类癌症，包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发肿瘤部位的转移、骨髓增生性疾病、慢性髓性白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合症、胃肠道间质瘤、结肠癌、眼部疾病，其特征为细胞过度增殖导致失明，包括各种视网膜病变、糖尿病视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺疾病、肥大细胞增多症、肥大细胞白血病以及由PDGFR-α激酶、PDGFR-β激酶、c-KIT激酶、cFMS激酶、c-MET激酶和任何上述激酶的癌变形式、异常融合蛋白和多态性引起的疾病。
• N-acyl ureas exhibiting anti-cancer and anti-proliferative activities
  申请人：Deciphera Pharmaceuticals, LLC

  公开号：US08278331B2

  公开（公告）日：2012-10-02

  Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

  本发明的化合物在哺乳动物癌症的治疗中具有实用性，特别是人类癌症，包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发性肿瘤部位的转移、骨髓增生性疾病、慢性髓细胞白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合征、胃肠间质肿瘤、结肠癌、眼部疾病，其特征为过度增殖导致失明，包括各种视网膜病变、糖尿病视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺疾病、肥大细胞增多症、肥大细胞白血病，以及由PDGFR-α激酶、PDGFR-β激酶、c-KIT激酶、cFMS激酶、c-MET激酶和任何上述激酶的癌变形式、异常融合蛋白和多态性引起的疾病。

表征谱图